#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3186	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2247	413.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1499	1499	C	457	C,T	384,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3186	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2247	413.5	0	HET	.	.	.	A69G	.	69	69	A	384	384	A	450	A,G	299,102	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4073	363.1	0	.	n	.	0	T695C	SNP	695	695	T	1296	1296	C	365	C,A	305,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4073	363.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1938	1938	A	399	A	340	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4073	363.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2572	2572	C	496	C,A	416,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4073	363.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3198	3198	T	429	T	361	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4073	363.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2646	2646	A	515	A,G	439,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	512	folP	855	855	100.0	folP.l6.c30.ctg.1	2430	62.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1502	1504	AGC	117;117;117	A;G;C,G	105;104;103,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1100	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3786	86.9	1	SNP	p	S91F	1	.	.	271	273	TTC	757	759	TTC	96;96;96	T;T;C	77;79;82	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1100	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3786	86.9	1	SNP	p	D95G	1	.	.	283	285	GGC	769	771	GGC	94;94;92	G;G;C	76;79;82	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1100	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3786	86.9	1	SNP	p	G95N	0	.	.	283	285	GGC	769	771	GGC	94;94;92	G;G;C	76;79;82	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	436	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1796	72.7	1	SNP	p	G45D	0	.	.	133	135	GGC	742	744	GGC	114;113;115	G,T;G;C	95,1;95;99	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	284	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1405	60.5	0	.	n	.	0	A197.	DEL	197	197	A	756	756	A	115	A	103	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1132	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3405	99.4	1	SNP	p	D86N	0	.	.	256	258	GAC	848	850	GAC	125;124;125	G;A;C,T	102;103;105,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1132	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3405	99.4	1	SNP	p	R87W	0	.	.	259	261	CGT	851	853	CGT	125;123;123	C;G;T,G	101;100;104,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1132	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3405	99.4	1	SNP	p	R87I	0	.	.	259	261	CGT	851	853	CGT	125;123;123	C;G;T,G	101;100;104,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1132	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3405	99.4	1	SNP	p	S87R	1	.	.	259	261	CGT	851	853	CGT	125;123;123	C;G;T,G	101;100;104,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1132	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3405	99.4	1	SNP	p	S88P	0	.	.	262	264	TCC	854	856	TCC	125;123;123	T;C;C	105;106;100	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	982	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3009	97.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1737	1739	GGC	130;131;130	G;G,A;C	107;109,1;107	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1515	1517	GCA	137;138;137	G,T;C;A	116,1;113;117	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1518	1520	ATC	137;137;136	A;T;C	118;116;114	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1530	1532	GTG	137;137;138	G;T;G,T	120;120;118,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1530	1532	GTG	137;137;138	G;T;G,T	120;120;118,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2034	2036	ACC	93;93;91	A;C;C	75;77;78	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2088	2090	GCG	88;88;89	G;C,G;G	72;63,1;66	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2088	2090	GCG	88;88;89	G;C,G;G	72;63,1;66	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2211	2213	AGC	85;86;85	A;G;C	73;70;71	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2220	2222	GGC	88;88;88	G;G,T;C	73;71,1;74	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	808	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2869	84.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2238	2240	CCG	88;88;88	C;C;G	70;72;70	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1130	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3619	93.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1907	1909	CCG	88;89;89	C;C;G	71;70;70	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	518	porA	1146	1146	99.91	porA.l6.c4.ctg.1	2273	68.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	793	793	C	79	C	71	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1193	1195	AAT	12;12;12	A;A;T	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1196	1198	AAT	12;12;12	A;A;T	11;10;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1220	1222	GCA	10;10;10	G;C;A	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1243	1245	GTA	9;9;9	G;T;A	8;8;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1249	1251	AAC	9;9;9	A;A;C	8;8;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1253	1257	TGGCG	9;9;9;9;9	T;G;G;C;G	8;7;8;8;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1259	1261	GCT	8;8;7	G;C;T	7;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1319	1321	TTA	8;8;8	T;T;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1364	1366	CAT	8;8;8	C;A;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1367	1369	AGT	8;8;8	A;G;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	295	90.3	porB1a.l15.c4.ctg.1	1463	16.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1376	1378	TAC	7;7;7	T;A;C	5;5;5	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	711	713	GAA	139;139;139	G;A;A	113;114;115	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	999	1001	GAT	124;124;124	G;A;T	108;102;106	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1122	1124	TCA	120;120;119	T;C;A	102;102;100	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1251	1253	GTC	124;122;123	G;T;C	106;104;102	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1263	1265	TCT	121;121;121	T;C;T	103;104;106	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1581	1583	GCA	126;126;127	G;C;A	104;103;105	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	1	SNP	p	G120K	1	.	.	358	360	AAG	957	959	AAG	124;126;126	A;A,C;G	109;107,1;109	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	1	SNP	p	D121N	0	.	.	361	363	GAC	960	962	GAC	126;126;127	G;A,T;C	107;108,1;110	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	610	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2110	86.5	1	SNP	p	A121D	1	.	.	361	363	GAC	960	962	GAC	126;126;127	G;A,T;C	107;108,1;110	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1976	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5389	110.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	306	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1416	64.7	1	SNP	p	V57M	1	.	.	169	171	ATG	661	663	ATG	126;127;128	A;T;G	116;117;116	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
